| 王恩行,周军怀,褚雪菲,等.丹红注射液联合依达拉奉对急性脑梗死病人的临床研究[J].安徽医药,2021,25(9):1881-1885. |
| 丹红注射液联合依达拉奉对急性脑梗死病人的临床研究 |
| Clinical study of the Danhong injection combined with edaravone in the treatment of acute cerebral infarction |
| |
| DOI：10.3969/j.issn.1009-6469.2021.09.044 |
| 中文关键词: 脑梗死 丹红注射液 依达拉奉注射液 血清炎性因子 生活质量 |
| 英文关键词: Brain infarction Danhong injection Edaravone Serum inflammatory factors Quality of life |
| 基金项目: |
|
| 摘要点击次数: 1400 |
| 全文下载次数: 389 |
| 中文摘要: |
| 目的观察丹红注射液联合依达拉奉对急性脑梗死病人的血清炎性因子、临床治疗效果及对神经功能恢复和生活质量的影响。方法将 2016年 1月至 2018年 12月三亚市中医院老年内科收治的 136例急性脑梗死病人，按 1∶1比例通过 SAS软件生成的 136个随机数字随机分为试验组和对照组，各 68例，进行为期 14 d的治疗。其中对照组采用依达拉奉射液治疗，试验组在对照组的基础上联合丹红注射液进行治疗。测定两组病人在治疗前后的相关血清炎性因子如白细胞介素 -6(IL-6)、超敏 C反应蛋白( hs-CRP)、肿瘤坏死因子 -α(TNF-α)及降钙素原水平，并采用美国国立卫生研究院卒中量表( NIHSS)和 Barthel指数评价经治疗后两组病人的神经功能状态变化情况及日常生活活动能力的改善情况，观察丹红注射液联合依达拉奉对病人的血清炎性因子、临床疗效及生活质量的影响。结果治疗 14 d后，试验组病人的总有效率( 86.76%)明显优于对照组( 66.18%)(P <0.043)。治疗前， IL-6、hs-CRP、TNF-α和降钙素原水平在两组间的差异无统计学意义( P>0.05)；治疗后两组炎性因子都显著降低，但试验组病人的各炎性因子的含量显著低于对照组(P<0.05)；治疗前，两组病人间的 NIHSS量表和 Barthel指数评分差异无统计学意义( P>0.05)；但经治疗后， NIHSS评分在试验组( 6.27±1.24)分显著低于对照组( 11.42±2.28)分( P<0.05)，而 Barthel指数试验组( 87.37±9.42)分显著高于对照组试验组( 71.82±6.13)分( P<0.05)。结论丹红注射液联合依达拉奉能提高临床的治疗效果，降低急性脑梗死病人的血清炎性因子 hs-CRP、TNF-α、IL-6和降钙素原的水平，从而有效保护神经元，促进病人神经功能的恢复以及改善病人的生活质量。 |
| 英文摘要: |
| Objective To observe the effects of Danhong injection combined with edaravone in the treatment of acute cerebral infarction (ACI) and its influence on the levels of serum inflammatory factors, nerve function recovery, clinical efficacy, and quality of life.Methods A total of 136 patients with ACI admitted to the Department of Geriatrics, Sanya Hospital of Traditional Chinese Medicinefrom January 2016 to December 2018 were randomly divided into two group (experimental group and control group, 68 cases eachgroup) according to the 1∶1 ratio, and the treatment was carried out for 14 days. The control group was given the Edaravone injectiontreatment, and the experimental group was givern the Danhong injection combined with Edaravone injection treatment. The levels of related serum inflammatory factors such as interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α) and procalcitonin before and after treatment in the two groups were determined, and the National Institutes of Health StrokeScale (NIH Stroke Scale, NIHSS) and Barthel index were used to evaluate the changes in neurological function status and improvementin activities of daily living. The effects of Danhong injection combined with edaravone on patients' serum inflammatory factors, clinical efficacy and quality of life were observed.Results After 14 days of treatment, the total effective rate of in the test group (86.76%) wassignificantly better than that in the control group (66.18%) (P<0.043). Before treatment, there was no significant difference in the levels of IL-6, hs-CRP, TNF-α and procalcitonin between the two groups (P>0.05); after treatment, the levels of inflammatory factors in thetwo groups were significantly reduced, but the levels of inflammatory factors in the test group were significantly lower than those of thecontrol group (P<0.05); before treatment, there was no significant difference in NIHSS scale and Barthel index scores between the two groups (P>0.05); but after treatment, the NIHSS score in the experimental group (6.27±1.24) was significantly lower than that in thecontrol group (11.42±2.28) (P<0.05), while the Barthel index in the test group (87.37±9.42) was significantly higher than that in the control group (71.82±6.13) (P<0.05).Conclusion Danhong injection combine with edaravone can improve the clinical treatment effect and reduce the serum inflammatory factors (hs-CRP, TNF-α, IL-6 and procalcitonin) levels in patients with acute cerebral infarc tion, thereby effectively protecting neurons, promoting the recovery of the patient's nerve function and improving the patient's quality oflife. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
